FRI0196 TREATMENT OF SYSTEMIC LUPUS ERYTHEMATOSUS PATIENTS WITH THE IMMUNOPROTEASOME INHIBITOR KZR-616: RESULTS FROM THE FIRST 2 COHORTS OF AN OPEN-LABEL PHASE 1B DOSE ESCALATION TRIAL
Publication
, Conference
Furie, R; Bomba, D; Dall’era, M; Prieto, M; Anderl, J; Wang, J; Kirk, C; Goel, N
Published in: Poster Presentations
June 2019
Duke Scholars
Published In
Poster Presentations
DOI
Publication Date
June 2019
Publisher
BMJ Publishing Group Ltd and European League Against Rheumatism
Conference Name
Annual European Congress of Rheumatology, EULAR 2019, Madrid, 12–15 June 2019
Related Subject Headings
- Arthritis & Rheumatology
- 3204 Immunology
- 3202 Clinical sciences
- 1117 Public Health and Health Services
- 1107 Immunology
- 1103 Clinical Sciences
Citation
APA
Chicago
ICMJE
MLA
NLM
Furie, R., Bomba, D., Dall’era, M., Prieto, M., Anderl, J., Wang, J., … Goel, N. (2019). FRI0196 TREATMENT OF SYSTEMIC LUPUS ERYTHEMATOSUS PATIENTS WITH THE IMMUNOPROTEASOME INHIBITOR KZR-616: RESULTS FROM THE FIRST 2 COHORTS OF AN OPEN-LABEL PHASE 1B DOSE ESCALATION TRIAL. In Poster Presentations. BMJ Publishing Group Ltd and European League Against Rheumatism. https://doi.org/10.1136/annrheumdis-2019-eular.1955
Furie, Richard, Darrin Bomba, Maria Dall’era, Massiel Prieto, Janet Anderl, Jinhai Wang, Christopher Kirk, and Niti Goel. “FRI0196 TREATMENT OF SYSTEMIC LUPUS ERYTHEMATOSUS PATIENTS WITH THE IMMUNOPROTEASOME INHIBITOR KZR-616: RESULTS FROM THE FIRST 2 COHORTS OF AN OPEN-LABEL PHASE 1B DOSE ESCALATION TRIAL.” In Poster Presentations. BMJ Publishing Group Ltd and European League Against Rheumatism, 2019. https://doi.org/10.1136/annrheumdis-2019-eular.1955.
Furie R, Bomba D, Dall’era M, Prieto M, Anderl J, Wang J, et al. FRI0196 TREATMENT OF SYSTEMIC LUPUS ERYTHEMATOSUS PATIENTS WITH THE IMMUNOPROTEASOME INHIBITOR KZR-616: RESULTS FROM THE FIRST 2 COHORTS OF AN OPEN-LABEL PHASE 1B DOSE ESCALATION TRIAL. In: Poster Presentations. BMJ Publishing Group Ltd and European League Against Rheumatism; 2019.
Furie, Richard, et al. “FRI0196 TREATMENT OF SYSTEMIC LUPUS ERYTHEMATOSUS PATIENTS WITH THE IMMUNOPROTEASOME INHIBITOR KZR-616: RESULTS FROM THE FIRST 2 COHORTS OF AN OPEN-LABEL PHASE 1B DOSE ESCALATION TRIAL.” Poster Presentations, BMJ Publishing Group Ltd and European League Against Rheumatism, 2019. Crossref, doi:10.1136/annrheumdis-2019-eular.1955.
Furie R, Bomba D, Dall’era M, Prieto M, Anderl J, Wang J, Kirk C, Goel N. FRI0196 TREATMENT OF SYSTEMIC LUPUS ERYTHEMATOSUS PATIENTS WITH THE IMMUNOPROTEASOME INHIBITOR KZR-616: RESULTS FROM THE FIRST 2 COHORTS OF AN OPEN-LABEL PHASE 1B DOSE ESCALATION TRIAL. Poster Presentations. BMJ Publishing Group Ltd and European League Against Rheumatism; 2019.
Published In
Poster Presentations
DOI
Publication Date
June 2019
Publisher
BMJ Publishing Group Ltd and European League Against Rheumatism
Conference Name
Annual European Congress of Rheumatology, EULAR 2019, Madrid, 12–15 June 2019
Related Subject Headings
- Arthritis & Rheumatology
- 3204 Immunology
- 3202 Clinical sciences
- 1117 Public Health and Health Services
- 1107 Immunology
- 1103 Clinical Sciences